A1M Pharma AB has changed its name to Guard Therapeutics International AB
Oxygen is a prerequisite for life. But there are times when the body begins to transform oxygen into substances that cause oxidative stress. This can lead to very serious damage on organs and tissue, such as acute kidney injury.
Acute kidney damage and oxidative stress – a global challenge
Oxidative stress in the kidney can for example appear due to invasive surgical interventions, chemotherapy, transplants and sepsis. Acute kidney injury is a dreaded consequence; a condition that quickly leads to impaired kidney function, with negative effects on essentially all bodily functions. Without functioning kidneys, life-supporting dialysis is a necessity.
More than 13 million people are affected by acute kidney damage every year. The mortality is high, and survivors are at risk of developing a chronically reduced kidney function, with all the implications of that in terms of increased morbidity and reduced quality of life. There is a substantial risk of mortality or severe and chronic consequences from acute kidney injuries, but unfortunately there are no effective therapies available today that address the cause of the damage.
Acute kidney damage associated with heart surgery – our focus
We have chosen to initially focus the development of ROSgard on the indication acute kidney damage associated with heart surgery. Considering ROSgard's mode of action and the very convincing preclinical results we have obtained from several independent preclinical studies, our assessment is that this indication is very attractive. Moreover, this indication offers a number of developmental advantages, for example a large patient base, relatively short duration of treatment, and a well-defined set of efficacy parameters that are accepted by the regulatory authorities.
About us and our operating activities.Read more